Form 4: Belite Bio CSO Nathan Mata Executes Stock Sale

Chief Scientific Officer Nathan L. Mata sold 666 American depositary shares of Belite Bio, Inc. via a Rule 10b5-1 trading plan.

Summary

• Nathan L. Mata, Chief Scientific Officer of Belite Bio, Inc., sold a total of 666 American depositary shares (ADS) on May 7, 2026.
• The transactions were executed in multiple tranches at weighted average prices ranging from $152.4473 to $155.2533 per share.
• Following these transactions, the reporting person holds 0 ADS directly.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be optically negative, the use of a pre-established 10b5-1 plan indicates the sale was scheduled well in advance for personal financial planning.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without concerns regarding non-public information.

Negatives

• The transaction represents a complete divestment of the reporting person's direct holdings of American depositary shares as of the filing date.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in the company's short-term growth prospects, despite the pre-planned nature of the sale.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice in the biotechnology sector, often used by executives to manage personal liquidity while maintaining compliance with SEC regulations.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives in the pharmaceutical and biotech sectors to avoid allegations of insider trading.

Stakeholder Impact

• Shareholders should note the reduction in direct equity ownership by the Chief Scientific Officer, though the pre-planned nature mitigates concerns regarding potential negative sentiment.

Key Dates

Keywords

Belite Bio, BLTE, Insider Trading, Form 4, Nathan Mata, Biotech